Výsledky vyhledávání - "Ming Zheng, MD"

Akademický článek

Predicting the effectiveness of omalizumab in patients with refractory chronic rhinosinusitis with nasal polyps comorbid with asthma based on inflammatory biomarkers

Autor: Yutong Sima, MD, Ming Zheng, MD, Yan Zhao, PhD, Siqi Ge, PhD, Chengyao Liu, MD, Ping Wang, BS, Xiangdong Wang, MD, PhD, Luo Zhang, MD, PhD

Publikováno v: World Allergy Organization Journal, Vol 18, Iss 1, Pp 101009- (2025)

Background: The treatment of refractory chronic rhinosinusitis with nasal polyps (CRSwNP) with omalizumab has been well studied based on clinical evaluation. Nevertheless, ideal quantitative or qualitative biomarkers for predicting a different respon

Externí odkaz: https://doaj.org/article/a41530d2b11c4e1ea39f0c7ce166b9e0

Zobrazit plný text záznamu

Akademický článek

Revision surgery versus biologic treatment with omalizumab in recurrent chronic rhinosinusitis with nasal polyps: An analysis of cost-utility and clinical outcomes

Autor: Yutong Sima, MS, Jing Zhang, MS, Ming Zheng, MD, Yan Zhao, PhD, Xiangdong Wang, MD, PhD, Luo Zhang, MD, PhD

Publikováno v: World Allergy Organization Journal, Vol 16, Iss 12, Pp 100846- (2023)

Background: Both revision surgery and omalizumab are recommended therapies for the treatment of recurrent chronic rhinosinusitis with nasal polyps (CRSwNP) and can improve patients' clinical symptoms and quality of life (QoL). The aim of this study w

Externí odkaz: https://doaj.org/article/c18f1dca3b3d4ef498312d12d6a5445f

Zobrazit plný text záznamu

Akademický článek

Clinical effectiveness and potential predictability of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps and asthma based on the noninvasive markers – A real-life prospective study

Autor: Ming Zheng, MD, PhD, Yutong Sima, MD, Chengyao Liu, MD, PhD, Jinming Zhao, MD, Shan Shao, MD, Xinmao Wang, MD, Yue Wang, MD, Feifei Cao, BS, Wei Xiong, BS, Xiangdong Wang, MD, PhD, Luo Zhang, MD, PhD

Publikováno v: World Allergy Organization Journal, Vol 15, Iss 10, Pp 100702- (2022)

Background: Clinical studies on the effectiveness of omalizumab in patients with difficult-to-treat chronic rhinosinusitis with nasal polyps (CRSwNP) and asthma are scarce in China. Moreover, identifying potential biomarkers predicting its efficacy r

Externí odkaz: https://doaj.org/article/606e44a5fabf49928e8fe670ae2564ac

Zobrazit plný text záznamu